Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
about
Tapentadol for chronic musculoskeletal pain in adultsNeuropathic low back pain in clinical practiceTapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.Successful use of stellate ganglion block and a new centrally acting analgesic with dual mode of action in a resistant temporomandibular joint painReady conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended releaseA pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathyTapentadol for Cancer Pain Management: A Narrative Review.Narcotic bowel syndrome and opioid-induced constipation.Unique pharmacology of tapentadol for treating acute and chronic pain.Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.Palmitoylethanolamide in the Treatment of Failed Back Surgery SyndromeOpioid-induced bowel dysfunction.Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.Serotonin Syndrome in Tapentadol Literature: Systematic Review of Original Research.Tapentadol Extended Release in the Treatment of Severe Chronic Low Back Pain and Osteoarthritis Pain.Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study
P2860
Q24187807-6B256D45-70A3-4314-B990-70E44D0A63C4Q28073412-6F3BC30B-D738-418C-803B-8268F5A3AB2BQ31128284-BA2920B0-13B7-468E-8610-83364B3C4A40Q33691651-9A763A1E-645A-4F73-9166-4B6DF2DC758FQ33775071-6B05486C-76D8-4A00-9F4D-B30C6C0008CBQ34990241-DB0A7E98-FDFD-46FE-A746-CA7FD2F1428DQ36248445-A8C9FE87-BEE5-4530-A2C0-7386F5E5AF17Q38245693-937B5516-40DD-4175-8288-6558F015A313Q38980690-8ACBBA56-C9F9-4689-8C37-9BC8FB5313CCQ39208211-BB2FB52F-C8C3-42F3-A3AA-D07EFA828BEFQ41508796-26ABBCAB-1F53-4676-8FFA-867AE3F6D6B5Q42323281-A1DBAEC4-EA19-4E0D-B20A-68BB925B4142Q47914794-6EAEF640-DB94-4AEC-A552-11AA35A28BF9Q50035203-E4AC4E8A-7189-4A77-ACD0-9E647D0FE4EEQ52603231-9A4544D5-F0AB-4F76-A6CE-76032B6B719DQ58912037-7B8D4490-6925-416C-A829-4CCD52D770A9
P2860
Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Tapentadol prolonged release v ...... an open-label, phase 3b study.
@en
Tapentadol prolonged release v ...... an open-label, phase 3b study.
@nl
type
label
Tapentadol prolonged release v ...... an open-label, phase 3b study.
@en
Tapentadol prolonged release v ...... an open-label, phase 3b study.
@nl
prefLabel
Tapentadol prolonged release v ...... an open-label, phase 3b study.
@en
Tapentadol prolonged release v ...... an open-label, phase 3b study.
@nl
P2093
P2860
P1433
P1476
Tapentadol prolonged release v ...... an open-label, phase 3b study
@en
P2093
Dietmar Falke
Ilona Steigerwald
Michael Schäfer
Rafael Gálvez
P2860
P2888
P304
P356
10.1007/S12325-013-0015-6
P407
P50
P577
2013-03-07T00:00:00Z